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Abstract
Background. Achieving normohydration remains a non-
trivial issue in haemodialysis therapy. Guiding the
haemodialysis patient on the path between fluid overload
and dehydration should be the clinical target, although it
can be difficult to achieve this target in practice. Objec-
tive and clinically applicable methods for the determina-
tion of the normohydration status on an individual basis are
needed to help in the identification of an appropriate target
weight.
Methods. The aim of this prospective trial was to guide
the patient population of a complete dialysis centre to-
wards normohydration over the course of approximately
1 year. Fluid status was assessed frequently (at least
monthly) in haemodialysis patients (n = 52) with the body
compositionmonitor(BCM),whichisbasedonwholebody
C   The Author 2009. Published by Oxford University Press [on behalf of ERA-EDTA].
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bioimpedance spectroscopy. The BCM provides the clini-
cian with an objective target for normohydration. The pa-
tientpopulationwasdividedintothreegroups:thehyperhy-
drated group (relative fluid overload >15% of extracellular
water (ECW); n = 13; Group A), the adverse event group
(patients with more than two adverse events in the last
4 weeks; n = 12; Group B) and the remaining patients
(n = 27; Group C).
Results. In the hyperhydrated group (Group A), fluid over-
load was reduced by 2.0 L (P < 0.001) without increasing
theoccurrenceofintradialyticadverseevents.Thisresulted
in a reduction in systolic blood pressure of 25 mmHg (P =
0.012). Additionally, a 35% reduction in antihypertensive
medication (P = 0.031) was achieved. In the adverse event
group (Group B), the fluid status was increased by 1.3 L
(P=0.004)resultingina73%reductioninintradialyticad-
verse events (P < 0.001) without significantly increasing
the blood pressure.
Conclusion. The BCM provides an objective assessment
of normohydration that is clinically applicable. Guiding
the patients towards this target of normohydration leads to
better control of hypertension in hyperhydrated patients,
less intradialytic adverse events and improved cardiac
function.
Keywords: adverse event; bioimpedance spectroscopy; fluid overload;
hypertension; normohydration
Introduction
Adequate fluid management plays an important role in the
treatment of haemodialysis patients. It is well accepted
that chronic fluid overload causes left ventricular hyper-
trophy [1], while, conversely, dehydration is linked to the
occurrence of intradialytic adverse events [2]. Both fluid
overload and dehydration are linked to an increased mor-
bidity in haemodialysis patients. Guiding the patient along
the narrow path between the deleterious effects of fluid
overload and dehydration [3,4] can be difficult. However,
the availability of a target provided by a practical clinical
method could help in the navigation of the patient along
this path [5]. As fluid overload and dehydration both influ-
ence the extracellular water, this target should be based on
the concept of an individual normal extracellular volume
(normohydration).
Several studies report the improvement of fluid status
and outcome when switching haemodialysis patients to a
different dialysis modality such as long or daily dialysis
[6,7] or when introducing a low-salt diet [8]. It has been
shown previously that patients suffering from hyperhydra-
tionof>15%ofECWarepronetoasignificantlyincreased
mortality risk [9]. Despite these findings, no data so far
have demonstrated the possible improvement of a prevalent
patient population when introducing the target of normo-
hydration for volume therapy.
In this study, a new bioimpedance spectroscopy device
for body composition measurement was used to determine
the normohydration weight. The body composition mon-
itor (BCM) provides an objective target for the normal
Table 1. Comparison of the population used for the primary analysis and
the excluded/deceased patients
All patients in primary Excluded—deceased
analysis (initial) patients (initial)
N5 2 1 1
BPsys_pre [mmHg] 153 ± 24 145 ± 22
BPdia_pre [mmHg] 82 ± 13 65 ± 17 p < 0.05
FOpre/ECW [%] 8.6 ± 9.3 9.1 ± 9.2
FOpost/ECW [%] −6.3 ± 14 −7.9 ± 16.9
70 recruited and baseline measurement
63 middle of observation period
52 end of study + complete dataset
6 died
1 dropout
5 died
6 dropout
January 2008
August 2006 
Fig. 1. Flow of patients through the study.
volume status (normohydration weight) in an individual
patient without the need for a reference population. Nor-
mohydration weight was used together with conventional
clinical methods to determine fluid overload of all patients
in one dialysis centre and to adjust the patients’ fluid sta-
tus if necessary. The aim was to reduce fluid overload in
hyperhydrated patients whilst minimizing the frequency of
intradialytic adverse events.
Methods
Patients
Using the available patient population of one dialysis centre in the Czech
Republic, a total of 70 patients were included in the study. These patients
representedthecompletepatientpopulationoftherespectivecentreinAu-
gust 2006 and additionally all patients starting renal replacement therapy
between the 1 August 2006 and the 1 August 2007. Patients with pace-
makers or large metallic implants were excluded from the study because
of possible adverse effects with the bioimpedance spectroscopy measure-
ment. Eleven patients died in the study period, whereof 3 died within the
first 6 month after starting the renal replacement therapy. Seven patients
had to be censored because they were transplanted or left the centre. Only
patients that covered the complete study period (n = 52) were included
in the analysis. Table 1 shows that there is no significant difference in
terms of systolic blood pressure and fluid status between the study analy-
sis group and the excluded/deceased patients. Figure 1 presents the patient
flow through the study. In total the 52 patients were monitored during an
observation period of 400 ± 134 days with 569 BCM measurements. All
patients had given informed consent, and the study was approved by the
local ethical committee. The achieved treatment time was 5 h and high-
flux membranes were used throughout with 90% of patients receiving
convective treatments and 6.2% being dialysed by a catheter.
Determination of normohydration/achieving normohydration
The BCM (Fresenius Medical Care) was used to determine the fluid over-
load and the weight representing normohydration on the basis of a whole-
body bioimpedance spectroscopy measurement [10]. The resistance and
reactance were measured by the BCM at 50 discrete frequencies cover-
ing the frequency spectrum from 5 to 1000 kHz. The extracellular and
the intracellular resistance were obtained on the basis of a Cole model
[11,12]. Using these resistances, the extracellular and intracellular fluid540 P. Machek et al.
volumes and total body water were calculated from a fluid model [13].
These fluid volumes were then used to determine the body composition
in terms of fluid overload, normally hydrated lean tissue and normally
hydrated adipose tissue [14].
It has been shown elsewhere that the spectroscopy measurement tech-
nique has high reproducibility [15–17] and specificity [18]. Extensive
validation of the fluid volumes and body composition has been per-
formed against reference methods involving healthy volunteers and pa-
tients [13,19,20]. The determination of fluid overload was validated using
expert clinical assessment [21] and reduction in fluid status by ultrafiltra-
tion [22].
In this study, BCM measurements were performed after a short dialysis
interval pre-dialysis with the patient in a supine position directly before
the dialysis treatment. The electrodes were fixed to the hand and foot
on one side of the body. Patients rested for 5 min before performing
the BCM measurement. All nurses in the centre were trained to use the
BCM. If any erroneous measurements were detected by the BCM on the
basis of a measurement quality indicator, the respective measurement was
repeated by the nurse. The post-fluid status was assessed by subtracting
the intradialytic weight loss from the fluid overload of the pre-dialysis
measurement. The time-averaged fluid overload (TAFO) was calculated
asthemeanbetweenthepre-dialysisandthepost-dialysisfluidstatus,thus
assuming a linear accumulation of fluid in the interdialytic period.
InadditiontothefluidoverloadmeasurementbytheBCM,thepatients’
fluid status was assessed clinically, taking into account the blood pressure
and signs and symptoms of hypo- and hypervolaemia. Where available the
patients’ annual echocardiographic measurement was used in the overall
assessment (92% of patients).
End-points of the study
Theprimaryend-pointsoughtwastoachievenormohydrationinthewhole
studypopulation.Inthepre-dialysisstate,amaximalrelativefluidoverload
(fluid overload relative to the extracellular water) of FO/ECW <15% was
allowed—this is comparable to an absolute fluid overload of 2.5 L (in the
populationaverage).Arelativefluidoverloadbetween−6%and6%(resp.
−1.1 L and 1.1 L—in the population average) [23] post-dialysis was the
secondary end-point desired.
Post-weight reduction was performed in steps <0.5 kg/week (<0.7%
ofdryweight),andtheantihypertensivemedicationwasrevisedinparallel
with changes in fluid status. The patients were measured with the BCM
once per month if flesh weight was considered stable—in unstable phases
the patients were measured on a weekly basis.
Clinical information
The number of antihypertensive agents prescribed at the time of the BCM
measurement was recorded for analysis, and agents prescribed for cardio-
protective reasons were not included. Over the course of the study, the
administration of erythropoietin was changed from subcutaneous to intra–
vascular, and the erythropoietin type was changed from Eprex to Aranesp.
As a discussion is ongoing about the conversion factor between Eprex
and Aranesp, the haemoglobin data and the erythropoietin data were not
included in the analysis.
The blood pressure was measured following the proposals by Agarwal
[24]. To improve the reproducibility of the blood pressure measurement,
the recordings of six previous dialysis sessions were averaged.
The intradialytic adverse events were collected for the interval of 12
haemodialysis treatments prior to the day of the respective BCM mea-
surement of fluid status. All adverse events were recorded that made an
intervention of the nursing staff necessary e.g. symptomatic hypotension
and cramps.
Albumin concentration was obtained from the most recent monthly
blood chemistry data prior to a BCM measurement. Additionally, eKt/V
was calculated using the Daugirdas formula [25]. The residual renal
function (RRF) was analysed on the basis of the routinely performed
monthly measurement. The ejection fraction was assessed before the
initial and after the last fluid status measurement by an experienced
echocardiographer—this data was available for 92% of the patients.
Data analysis
A period of at least 6 months was allowed for a correction of the fluid
status and to ensure the cardiovascular stability of the patients. In addition
to initial and last measurements, the BCM measurement occurring in the
Fig. 2. Example of reduction in fluid overload in a single patient from
Group A (hyperhydrated) over 18 months. The relative fluid overload is
shownpre-andpost-treatmentandthetwodottedlinesindicatethetrendof
thefluidreduction.Thefluidstatuspre-treatment(FOpre/ECW)isreduced
from 25% (4.9 L) to 20% (4 L) and finally to 12% (2.2 L). Over the same
timeinterval,thefluidstatusattheendofthetreatment(FOpost/ECW)was
reduced from 11% (1.9 L) to 3.3% (0.5 L) and finally to −8.9% (−1.1 L).
middle of the observation period was chosen allowing the observation
period to be analysed as two observation phases, as seen in Figure 2.
The changes in hydration status, blood pressure, body composition,
heart status, blood chemistry data and symptoms were analysed and the
following groups were identified retrospectively on the basis of the initial
assessment:
• Group All: all patients available for primary analysis (n = 52);
• Group A: hyperhydrated patients: 25% of all patients (n = 13) with a
fluid overload; FOpre/ECW>15% in the initial assessment;
• GroupB:adverseeventpatients:23%ofallpatients(n=12)presenting
more than two adverse events in the 4 weeks prior to the initial BCM
measurement;
• Group C: patients neither in Group A (hyperhydrated) nor in Group B
(adverse event) (n = 27).
Statistics
The analysis followed the per protocol analysis, thus the censored patients
were not included in the analysis. To analyse the changes induced by the
intervention, a pairwise multiple comparison procedure, following Dum’s
or Holm-Sidak’s method, was performed.
The significance of the changes between the initial, the mid and the
last measurement in each group and the differences between Groups A, B
and C were analysed. The level of significance was set to P = 0.05.
Results
Comparison between the groups
In the initial measurement, the blood pressure at the end
of the treatment was significantly higher in Group A com-
pared to Group B (P = 0.028). In contrast, the ejection
fraction (P = 0.024) was significantly lower in Group A
compared to the other two groups. The absolute fluid over-
loadandtherelativefluidoverload(FOandFO/ECW)were
significantly higher in Group A (hyperhydrated) both at the
start and at the end of the treatment (P < 0.001). Patients
in Group B presented more adverse events than those in the
other two groups (P = 0.024). In addition, the intradialytic
blood pressure change was significantly greater in Group B
(P = 0.004). At the time of the last measurement, the sys-
tolic blood pressure post-dialysis was found to be highest
in Group B (P = 0.026). No other significant differences
were observed. The number of patients achieving the de-
fined target for the pre- and post-dialytic fluid overload,Guided optimization of fluid status in haemodialysis patients 541
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Fig. 3. Fluid status changes in Group A (hyperhydrated. left) and Group B (adverse event. right). In these groups, the relative fluid status before dialysis
treatment is shown. Each box summarizes the results of the initial, the middle and the last measurements. Additionally, the target range for the relative
fluid overload before dialysis treatment (between 6% and 15%) is indicated. The boundaries of the boxes are the 25th and the 75th percentile. The
whiskers show the 10th and the 90th percentile, while the dots show outliers (5th and 95th percentiles).
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Fig. 4. Fluid status changes in Group A (hyperhydrated, left panel) and Group B (adverse event, right panel) after dialysis treatment including the target
range for the relative fluid overload after treatment (−6% to +6%). The boxes show the results of the initial, the middle and the last measurements.
increased by 66% (n = 12 at the start, n = 25 in the mid
and n = 20 at the end of the study).
Changes in Group A from the initial to the last
measurement
Figure 2 shows the change in fluid overload in one exem-
plary patient. Figures 3 and 4 and Table 2 indicate the fluid
statuschangesinthevariouspatientgroups.InGroupA,the
fluid overload was reduced significantly in the study period
(P < 0.001). A significant reduction in the systolic (P =
0.029) and diastolic (P = 0.042) blood pressure before
and after the treatment could be observed in Group A to-
gether with a reduction of the antihypertensive medication
(P = 0.031). The patients in Group A exhibited an increase
in the ejection fraction from 51.8 ± 9.8% to 58.4 ± 8%
(P = 0.021).
Changes in Group B from the initial to the last
measurement
Figures 3 and 4 show the increase in fluid status in Group
B. In this group, the fluid status was increased significantly
(P < 0.001). The recorded adverse events reduced signifi-
cantly from 25.7% ± 10% to 6.9% ± 7.8%, (P < 0.001),
whileallotherclinicalparametersincludingthebloodpres-
sure and the ejection fraction did not change.
Discussion
The availability of an objective, patient-specific determi-
nation of normohydration is of key importance for the im-
provement of fluid management in haemodialysis patients
[26]. Following initial measurements with the BCM in the
dialysis centre involved in this study, the fluid overload was
found to be FOpre/ECW >15% in 25% of patients. These
findingsareinagreementwitharecentpublicationshowing
that 25% of patients from a large haemodialysis population
exhibit a fluid overload of >2.5 L (FOpre/ECW>15%) be-
fore dialysis treatment [23]. Wizemann [27] showed that
this fluid overload leads to a more than 2-fold increase in
mortality risk.
The reason for the observed fluid overload in Group
A was further investigated. Fifty percent of the patients
in Group A were referred at a very late stage to the HD
treatment from the pre-ESRD care, 25% of all patients in
Group A were referred late after a failing transplant and
one patient was switched from PD to HD. In all these cases,
the high fluid overload was not unexpected, the late referral5
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Table 2. Comparison of the whole population and the subgroup analysis shown as the mean and the standard deviation
Group All Group A (hyperhydrated) Group B (adverse events) Group C (not A, not B)
N 52 13 = 25% of population 12 = 23% of population 27 = 52% of population
Months since the start of RRT 33.7 ± 51 36.8 ± 79 47.3 ± 44 21.7 ± 28
Diabetics 29% 43% 41% 21%
Initial Mid Last Initial Mid Last Initial Mid Last Initial Mid Last
Age (years) 61.7 ± 12.5 62.3 ± 12.5 62.8 ± 12.5 60.1 ± 11.1 60.5 ± 11.0 61.0 ± 11.0 58.3 ± 13.5 58.9 ± 13.5 59.5 ± 13.5 63.7 ± 12.7 64.3 ± 12.8 64.9 ± 12.8
Observation months 0 6.8 ± 3.1 13.2 ± 4.7 0 5.5 ± 3.1 11.0 ± 4.9 0 7.8 ± 3.2 14.6 ± 4.6 0 6.9 ± 3.0 13.8 ± 4.5
RRF (ml/24 h) 596 ± 700 376 ± 540◦ 337 ± 613+ 837 ± 778 509 ± 625 467 ± 594 304 ± 530 109 ± 192 104 ± 245+ 555 ± 665 441 ± 582 500 ± 708
BMI (kg/m2) 26.7 ± 5.9 26.8 ± 5.9 26.9 ± 5.8 24.7 ± 4.5 24.3 ± 4.1 24.4 ± 4.0 27.5 ± 7.7 28.2 ± 8.2 28.7 ± 8.0 27.2 ± 5.6 27.3 ± 5.4 27.3 ± 5.2
Weight (kg) 75.7 ± 16.6 75.8 ± 16.4 76.2 ± 16.7 76.5 ± 15.0 75.4 ± 13.6 75.5 ± 13.1 77.0 ± 20 79.0 ± 21.8 80.6 ± 22.0 74.5 ± 16.4 74.7 ± 15.6 74.8 ± 15.8
BPsys pre (mmHg) 153 ± 24 138 ± 27 148 ± 25 153 ± 14 139 ± 38 128 ± 24+ 155 ± 27 144 ± 24 159 ± 19 150 ± 27 140 ± 23 149 ± 22
BPdia pre (mmHg) 82 ± 13 71 ± 11 72 ± 16 87 ± 11 74 ± 11 67 ± 18+ 82 ± 15 72.6 ± 97 7 ± 98 0 ± 12 70 ± 12o 70 ± 13+
BPsys post (mmHg) 145 ± 31 138 ± 25 138 ± 29 158 ± 27 131 ± 25o 128 ± 25+ 124 ± 24 144 ± 24 145 ± 32 146 ± 32 136 ± 26 137 ± 27
BPdia post (mmHg) 77 ± 16 71 ± 12 66 ± 13 84 ± 15 72 ± 12o 64 ± 15++ 75 ± 16 74 ± 67 0 ± 12 74 ± 15 71.3 ± 14 65 ± 13+
Antihypertensive medication 1.0 ± 1.2 0.7 ± 1.0 0.5 ± 0.9 1.7 ± 1.5 1.3 ± 1.4 1.1 ± 1.3+ 0.5 ± 0.8 0.6 ± 1.0 0.3 ± 0.5 0.8 ± 1.0 0.4 ± 0.6 0.4 ± 0.6
Intradialytic weight loss
(% of weight)
3.2 ± 1.4 3.0 ± 1.1 3.4 ± 1.3 2.6 ± 1.5 3.9 ± 0.8 3.8 ± 1.4 3.7 ± 1.2 2.9 ± 1.3 3.5 ± 1.3 3.2 ± 1.4 2.7 ± 0.9 3.2 ± 1.3
eKt/V 1.6 ± 0.3 1.7 ± 0.4 1.8 ± 0.4 1.7 ± 0.3 1.7 ± 0.3 1.7 ± 0.3 1.7 ± 0.3 1.6 ± 0.3 1.7 ± 0.3 1.6 ± 0.4 1.7 ± 0.5 1.72 ± 0.4
Albumin (g/L) 36.7 ± 3.4 36.8 ± 3 37.7 ± 2.8 35.7 ± 3.5 37.9 ± 2.2 37.7 ± 3.7 37.6 ± 2.7 36.8 ± 2.2 37.6 ± 1.6 36.8 ± 3 36.5 ± 3.4 38.2 ± 2.2
Adverse events (% of
treatments)
6.7 ± 11.8 3.9 ± 10.7 3.7 ± 6.7 2.1 ± 5.2 2.3 ± 5.4 1.4 ± 3.2 25.7 ± 10 3.5 ± 6.6oo 6.9 ± 7.8++ 2.1 ± 4.4 5.3 ± 14 3.2 ± 6.5
Ejection fraction (%) 57.7 ± 8.0 NA 59.5 ± 6.5 51.8 ± 9.8 NA 58.4 ± 8.0+ 60.4 ± 7.2 NA 61.2 ± 6.3 59.3 ± 6.4 NA 59.3 ± 6.5
Extracellular water (ECW) (L) 17.5 ± 3.5 17.3 ± 3.2 17.3 ± 3.2 20.4 ± 3.0 18.4 ± 2.6oo 17.9 ± 2.0++ 16.2 ± 3.3 17.1 ± 3.7 17.6 ± 3.9 16.6 ± 3.1 16.9 ± 3.2 17.05 ± 3.3
Total body water (TBW) (L) 36.0 ± 6.7 35.2 ± 6.5 35.2 ± 6.6 40.4 ± 5.8 37.5 ± 5.8oo 36.8 ± 4.7++ 34.4 ± 7.1 34.8 ± 7.5 35.2 ± 8.1 34.5 ± 6.3 34.5 ± 6.4 34.6 ± 6.8
Time-averaged fluid overload
TAFO (L)
0.2 ± 1.9 0.6 ± 1.1 0.4 ± 1.1 3.0 ± 0.6 1.0 ± 0.9oo 0.7 ± 1.0++ −1.0 ± 0.9 0.3 ± 0.8oo 0.4 ± 0.6++ −0.1 ± 1.3 0.5 ± 1.2 0.4 ± 1.2
Fluid overload pre FOpre (L) 1.6 ± 1.8 1.7 ± 1.2 1.7 ± 1.1 4.0 ± 0.8 2.4 ± 0.9oo 2 ± 0.9++ 0.4 ± 0.8 1.4 ± 1.0o 1.7 ± 0.8+ 1.0 ± 1.3 1.5 ± 1.3 1.6 ± 1.3+
Fluid overload post FOpost (L) −0.7 ± 2.0 −0.5 ± 1.0 −0.8 ± 1.2 2.1 ± 0.8 −0.44 ± 0.8oo −0.7 ± 1.3++ −2.3 ± 1.2 −0.8 ± 0.8oo −1 ± 0.7++ −1.3 ± 1.4 −0.4 ± 1.2o −0.7 ± 1.3
FOpre/ECW (%) 8.6 ± 9.3 9.6 ± 6.9 9.9 ± 6.1 19.7 ± 3.1 12.8 ± 5 11.5 ± 5.2++ 2.6 ± 4.9 8.3 ± 6.2oo 10.1 ± 4.4++ 5.8 ± 8.3 8.6 ± 7.6 9.2 ± 7.2
FOpost/ECW (%) −6.3 ± 14.0 −3.7 ± 7.5 −5.6 ± 8.2 11.2 ± 3.2 −3.7 ± 5.9oo −5.0 ± 8.2++ −18 ± 10.2 −5.4 ± 5.4oo −6.9 ± 5.3++ −9.6 ± 11.0 −3.3 ± 8.8o −5.5 ± 9.4
oP < 0.05, ooP < 0.001 for initial vs. mid measurement, +P < 0.05, ++P < 0.001 for initial vs. last measurement, NA: not available.Guided optimization of fluid status in haemodialysis patients 543
remains a problem that needs to be addressed in the future
[28]. In Groups B and C, only 16% and 18.5% of patients
were late referrals, respectively.
Previous works have suggested that patients might ben-
efit from assessing and maintaining fluid status by an ob-
jective method [2,29,30]. Prior to the current study, there
have been no reports in the literature demonstrating the
achievement of normohydration in a complete dialysis
centre.
Thepurposeofthisstudywastoinvestigateifthepatients
might benefit from an improvement in fluid status towards
the normohydration range provided by the BCM [31].
It was decided that the weight representing the normo-
hydration target should be approached slowly and carefully
allowing the cardiovascular system sufficient time to adapt
to the changes in fluid status. The post-weight was changed
by <0 . 5k g( <0.7% of dry body weight) in 1 week. The
increase in post-weight in Group B (adverse event group)
was performed with the highest caution ensuring that there
was no occurrence of clinical signs of overhydration in the
interdialyticinterval.Webelievethatwhileitisimportantto
approach the target of normohydration slowly, it is equally
important not to lose sight of this target. Using this strat-
egy, it was possible to modify the fluid status in incident
and established dialysis patients towards normohydration
without causing additional intra- or interdialytic adverse
events. Furthermore, the reductions in fluid overload made
a significant reduction in the antihypertensive medication
achieveable.
Already after an observation period of 6 months, it was
possibletoobserveanimprovementinthepatientstatus.To
exclude any seasonal effects (initial measurement winter,
middle measurement summer, last measurement winter),
the observation period was extended to more than 1 year
(400 ± 139 days).
Benefits for patients in Group A
The benefits for patients in Group A caused by the
normalization of the fluid status were demonstrated by
the reduction in blood pressure and antihypertensive
medication.
Recently, Agarwal [32] could show in a randomized con-
trolled trial in hypertensive patients (n = 100) that a reduc-
tion in predialytic weight of 1 kg over an 8-week interval
resulted in a reduction of predialytic systolic blood pres-
sure of 6.6 mmHg. In our study, the hyperhdrated Group A
patients showed a comparable initial blood pressure (153 ±
14 mmHg vs. 159 ± 16 mmHg), but the reduction was
twice as large (12.5 mmHg per 1 L reduction of FO over
1 year) without an increase in intradialytic adverse events.
This might show the advantage of classifying the patients
by hydration status and targeting for the normohydration
status instead of using the probing for dry weight concept
in hypertensive patients.
In addition to the improvement in blood pressure, a con-
comitant increase in ejection fraction was observed. More
detailed analysis of the impact of a reduction in fluid over-
load on left ventricular hypertrophy and ejection fraction
should be the topic of further research.
Benefits for patients in Group B
The baseline rate of adverse events (4 weeks prior to
the initial BCM measurement) was found to be 25%
in patients of Group B. Group B patients presented
an elevated systolic blood pressure (BPsys pre_initial =
155 ± 27 mmHg) even though many patients were
normohydrated at the start and severely dehydrated at the
end of the dialysis session (FOpost_initial =− 2.3 ± 1.2 L).
In this group, the blood pressure might have been increased
due to non-fluid-linked reasons (vascular stiffness, renin
over activity,...). Thus, the blood pressure was used as an
indicator for increased fluid status, which was misleading
in this patient group. It must be highlighted that before the
study, no clinical methods for the detection of underhy-
dration were available in the participating dialysis centre.
Increasing the fluid status very carefully by 1.3 L led to
a significant reduction in the intradialytic adverse events
(reduction by 76%). It is essential to separate patients with
hypertension due to fluid overload from patients in whom
the hypertension has other reasons [23].
Randomized controlled trials would strengthen the find-
ings reported in this study. In order to better demonstrate
improvements in the cardiac function such as the reduction
of left ventricular hypertrophy, other techniques involving
magnetresonancetomographyshouldbeemployed[33,34].
Inthecurrentstudy,thedietofthepatientswasnotreviewed
as proposed by various working groups [8,35]. Therefore,
there is a scope in future studies to investigate the effects
of dietary salt intake using the analysis methods we have
proposed.
Conclusion
The fluid status of haemodialysis patients can be quite dif-
ferent, even if they are managed by the same clinical team.
The advantage of an objective target in routine clinical
practice is self-evident. We have shown that the normohy-
dration target determined with the BCM can be achieved
in all prevalent and incident patients of one dialysis cen-
tre. Increasing the fluid status slightly in patients who pre-
sented intradialytic adverse events and were dehydrated re-
duced the intradialytic events dramatically. Reduction of
fluid overload, hypertension and antihypertensive medica-
tionwaspossiblebyaslowreductionofpost-dialysisweight
in hyperhydrated patients.
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